Seizure is one of the most frequent neurological complication and morbid phenomenon among children receiving chemotherapy for acute lymphoblastic leukemia. As overall survival of children with acute lymphoblastic leukemia is improving, now the challenge is to reduce treatment-related adverse effect. However, not much is known about the etiology and natural history of these seizure in our pediatric population. This is a single centered study conducted in the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University. This prospective observational study was conducted over a period of 1 year from May 2017 to April 2018. A total of 105 patients aged 1 year to 17.9 years newly diagnosed as acute lymphoblastic leukemia were the study population. This study showed that in five (33.3%) patients, the underlying cause was suspected intracranial hemorrhage and it was the most common cause. All these five patients had features of severe sepsis and upper motor neuron sign associated with severe thrombocytopenia. Among them three had coagulopathy. Three (20%) patients had CNS leukemic infiltration. Suspected meningitis was attributed as the possible cause of seizure in two (13.33%) patients. Other identifiable causes were brain abscess in one patient, multiple cerebral infarction in one patient, hypertensive encephalopathy in one patient, and vincristine-induced neurotoxicity in one patient. In one patient no identifiable cause was found. Among 15 patients with seizure five (33.3%) patients were improved and completed induction remission chemotherapy. Ten (66.7%) patients died. In this study, we found sepsis and coagulopathy as the major underlying cause of seizure. Outcome was found very dismal in patients who developed seizure.
{"title":"Etiology and Outcome of Seizures in Children during Induction Remission Chemotherapy for Acute Lymphoblastic Leukaemia","authors":"S. A. Soma, C. Jamal, Indira Chowdhury","doi":"10.1055/s-0042-1748322","DOIUrl":"https://doi.org/10.1055/s-0042-1748322","url":null,"abstract":"Seizure is one of the most frequent neurological complication and morbid phenomenon among children receiving chemotherapy for acute lymphoblastic leukemia. As overall survival of children with acute lymphoblastic leukemia is improving, now the challenge is to reduce treatment-related adverse effect. However, not much is known about the etiology and natural history of these seizure in our pediatric population. This is a single centered study conducted in the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University. This prospective observational study was conducted over a period of 1 year from May 2017 to April 2018. A total of 105 patients aged 1 year to 17.9 years newly diagnosed as acute lymphoblastic leukemia were the study population. This study showed that in five (33.3%) patients, the underlying cause was suspected intracranial hemorrhage and it was the most common cause. All these five patients had features of severe sepsis and upper motor neuron sign associated with severe thrombocytopenia. Among them three had coagulopathy. Three (20%) patients had CNS leukemic infiltration. Suspected meningitis was attributed as the possible cause of seizure in two (13.33%) patients. Other identifiable causes were brain abscess in one patient, multiple cerebral infarction in one patient, hypertensive encephalopathy in one patient, and vincristine-induced neurotoxicity in one patient. In one patient no identifiable cause was found. Among 15 patients with seizure five (33.3%) patients were improved and completed induction remission chemotherapy. Ten (66.7%) patients died. In this study, we found sepsis and coagulopathy as the major underlying cause of seizure. Outcome was found very dismal in patients who developed seizure.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46934204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The study includes preliminary phytochemical screening and assessing alleviative effects of ethanolic extract of Bambusa vulgaris shoots and Opuntia ficus-indica fruits (EEBO) on azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colorectal cancer in rodents. Acute oral toxicity study was performed to find the therapeutic dose of EEBO. In animals, cancer was induced by single injection of AOM 10 mg/kg intraperitoneally followed by supply of three repeated cycles of 2.5% of DSS solution. Then animals were treated with EEBO from third day of experiment and treatment was continued throughout the experimental period. The anticancer effect was assessed by studying body weight (b. wt) changes, macroanatomy, antioxidant level, and microanatomy of colon. The phytochemical evaluation revealed the presence of alkaloid, glycoside, carbohydrate, and flavonoid in bamboo extract, whereas glycoside and flavonoid in cactus extract. The results found that EEBO increases the b. wt and level of antioxidants like sodium dismutase, glutathione, and catalase and meanwhile decreases malondialdehyde. Macroanatomy study indicated a decrease in the numbers of adenoma and inflammatory signs in the treated group when compared with diseased group. Histopathology revealed that the presence of EEBO improved the colon histoarchitecture similar to normal and masked the crypt appearance. Decreased chromosomal aberrations and micronucleus numbers were observed in EEBO treated group. Overall, results suggest that the EEBO 400 mg/kg exhibited highest activity compared with 200 and 100 mg/kg and the effect may be attributed to its antigenotoxic or antioxidant effect.
{"title":"Alleviative Effect of Herbal Extract Containing Phytoconstituents of Bambusa vulgaris and Opuntia ficus-indica against AOM/DSS-Induced Colorectal-Carcinoma-Bearing Mice","authors":"M. Komala, C. Ravishankar, Anbu Jayaram","doi":"10.1055/s-0042-1745729","DOIUrl":"https://doi.org/10.1055/s-0042-1745729","url":null,"abstract":"The study includes preliminary phytochemical screening and assessing alleviative effects of ethanolic extract of Bambusa vulgaris shoots and Opuntia ficus-indica fruits (EEBO) on azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colorectal cancer in rodents. Acute oral toxicity study was performed to find the therapeutic dose of EEBO. In animals, cancer was induced by single injection of AOM 10 mg/kg intraperitoneally followed by supply of three repeated cycles of 2.5% of DSS solution. Then animals were treated with EEBO from third day of experiment and treatment was continued throughout the experimental period. The anticancer effect was assessed by studying body weight (b. wt) changes, macroanatomy, antioxidant level, and microanatomy of colon. The phytochemical evaluation revealed the presence of alkaloid, glycoside, carbohydrate, and flavonoid in bamboo extract, whereas glycoside and flavonoid in cactus extract. The results found that EEBO increases the b. wt and level of antioxidants like sodium dismutase, glutathione, and catalase and meanwhile decreases malondialdehyde. Macroanatomy study indicated a decrease in the numbers of adenoma and inflammatory signs in the treated group when compared with diseased group. Histopathology revealed that the presence of EEBO improved the colon histoarchitecture similar to normal and masked the crypt appearance. Decreased chromosomal aberrations and micronucleus numbers were observed in EEBO treated group. Overall, results suggest that the EEBO 400 mg/kg exhibited highest activity compared with 200 and 100 mg/kg and the effect may be attributed to its antigenotoxic or antioxidant effect.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45035821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Khedr, Samia Abdel Fattah Sharaf, Ahmed Nagdy Abdel Aal, I. Dessouky, M. Soliman
Vitamin D has potent antiproliferative, prodifferentiative, and immune-modulatory effects. Vitamin D deficiency has been suggested to be very prevalent and there is growing evidence for the association between vitamin D deficiency and risk of breast cancer. The aim of this study was to evaluate the association of serum 25-hydroxyvitamin D [25(OH)D] level with breast cancer risk among Egyptian women. The current study included 40 breast cancer cases and 40 healthy control women. Serum 25(OH)D levels were measured using enzyme-linked immunosorbent assay for all women and together with other clinical factors were correlated to the risk of breast cancer. A total of 80 women including 40 breast cancer cases and 40 controls were included in this analysis. The clinical characteristics were well balanced with no significant difference between cases and controls regarding age, menopausal status, weight, height, body mass index, serum calcium, and phosphorus levels. The mean serum 25(OH)D level in cases (12.11 ng/mL) was significantly lower than in controls (19.77 ng/mL). Ninety percent of cases had 25(OH)D deficiency (<20 ng/mL) compared with 57.5% of the controls. After adjustment for potentially confounding variables, women with vitamin D deficiency were associated with a high significant risk of breast cancer compared to women with sufficient vitamin D with OR of 6.99 (95% CI = 2.01–24.32, p = 0.002). A significant association exists between vitamin D deficiency and the risk of breast cancer in Egyptian women.
{"title":"Serum 25-Hydroxyvitamin D Level and Breast Cancer Risk in Egyptian Females","authors":"M. Khedr, Samia Abdel Fattah Sharaf, Ahmed Nagdy Abdel Aal, I. Dessouky, M. Soliman","doi":"10.1055/s-0042-1748494","DOIUrl":"https://doi.org/10.1055/s-0042-1748494","url":null,"abstract":"Vitamin D has potent antiproliferative, prodifferentiative, and immune-modulatory effects. Vitamin D deficiency has been suggested to be very prevalent and there is growing evidence for the association between vitamin D deficiency and risk of breast cancer. The aim of this study was to evaluate the association of serum 25-hydroxyvitamin D [25(OH)D] level with breast cancer risk among Egyptian women. The current study included 40 breast cancer cases and 40 healthy control women. Serum 25(OH)D levels were measured using enzyme-linked immunosorbent assay for all women and together with other clinical factors were correlated to the risk of breast cancer. A total of 80 women including 40 breast cancer cases and 40 controls were included in this analysis. The clinical characteristics were well balanced with no significant difference between cases and controls regarding age, menopausal status, weight, height, body mass index, serum calcium, and phosphorus levels. The mean serum 25(OH)D level in cases (12.11 ng/mL) was significantly lower than in controls (19.77 ng/mL). Ninety percent of cases had 25(OH)D deficiency (<20 ng/mL) compared with 57.5% of the controls. After adjustment for potentially confounding variables, women with vitamin D deficiency were associated with a high significant risk of breast cancer compared to women with sufficient vitamin D with OR of 6.99 (95% CI = 2.01–24.32, p = 0.002). A significant association exists between vitamin D deficiency and the risk of breast cancer in Egyptian women.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43110092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Laghari, Z. Suchal, R. Avani, Daniyal Aziz Khan, A. Kabani, M. Nouman, S. Enam
Introduction MicroRNAs are a noncoding RNA involved in affecting several transcription and translation pathways. Their use has been discussed as potential predictors of several tumors. Their use as potential biomarker in glioma patients is still controversial. The purpose of this meta-analysis is to explore the possible role of such microRNAs in glioma patients. Methods After an extensive literature search done on PubMed and Embase, 20 studies were chosen for our analyses with the 9 discussing 11 tumor promoting microRNAs and 11 studies discussing 11 tumor suppressing microRNAs. The data needed was extracted from these studies including the hazard ratio that was used as the effect size for the purpose of our analysis. The needed analysis was performed using Stata and Excel. Results The pooled hazard ratio for our analysis with patients having a lower microRNA expression for tumor promoting microRNAs came to be 2.63 (p < 0.001), while the hazard ratio for patients with higher expression of tumor promoting microRNA was 2.47 (p < 0.001) with both results being statistically significant. However, as significant heterogeneity was observed a random effect model for analysis was used. Subgroup analysis was further performed using grade, cutoff value (mean or median), sample type (Serum or Blood), and Karnofsky performance score, all of them showing a high hazard ratio. Conclusion Our results showed that both tumor inhibitory and promoting microRNA can be used as prognostic tool in glioma patients with a poorer prognosis associated with a lower expression in tumor suppressive and higher expression in tumor promoting microRNA, respectively. However, to support this, future studies on a much larger scale would be needed.
{"title":"Prognostic Potential of MicroRNAs in Glioma Patients: A Meta-Analysis","authors":"A. Laghari, Z. Suchal, R. Avani, Daniyal Aziz Khan, A. Kabani, M. Nouman, S. Enam","doi":"10.1055/s-0042-1744448","DOIUrl":"https://doi.org/10.1055/s-0042-1744448","url":null,"abstract":"\u0000 Introduction MicroRNAs are a noncoding RNA involved in affecting several transcription and translation pathways. Their use has been discussed as potential predictors of several tumors. Their use as potential biomarker in glioma patients is still controversial. The purpose of this meta-analysis is to explore the possible role of such microRNAs in glioma patients.\u0000 Methods After an extensive literature search done on PubMed and Embase, 20 studies were chosen for our analyses with the 9 discussing 11 tumor promoting microRNAs and 11 studies discussing 11 tumor suppressing microRNAs. The data needed was extracted from these studies including the hazard ratio that was used as the effect size for the purpose of our analysis. The needed analysis was performed using Stata and Excel.\u0000 Results The pooled hazard ratio for our analysis with patients having a lower microRNA expression for tumor promoting microRNAs came to be 2.63 (p < 0.001), while the hazard ratio for patients with higher expression of tumor promoting microRNA was 2.47 (p < 0.001) with both results being statistically significant. However, as significant heterogeneity was observed a random effect model for analysis was used. Subgroup analysis was further performed using grade, cutoff value (mean or median), sample type (Serum or Blood), and Karnofsky performance score, all of them showing a high hazard ratio.\u0000 Conclusion Our results showed that both tumor inhibitory and promoting microRNA can be used as prognostic tool in glioma patients with a poorer prognosis associated with a lower expression in tumor suppressive and higher expression in tumor promoting microRNA, respectively. However, to support this, future studies on a much larger scale would be needed.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47871725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Many agents have been evaluated as maintenance therapy for metastatic colorectal cancer (mCRC), but there is no consensus on the optimal regimen. This study assessed the effect of single-agent capecitabine maintenance therapy on the survival outcomes of mCRC patients. A comprehensive literature search was performed according to prespecified inclusion and exclusion criteria for randomized controlled trials (RCTs) comparing capecitabine as maintenance monotherapy versus active monitoring for mCRC patients. Data on overall survival (OS), progression-free survival (PFS), time to tumor progression (TTP), adverse events, and quality of life (QoL) scores were extracted. Three RCTs with a total of 576 patients were included. Pooled analyses found neither OS benefit (HR:0.85, 95% CI:0.64–1.13) nor reduction in mortality at 24 months (RR:0.88, 95% CI:0.66–1.17) with capecitabine maintenance. Compared with active monitoring, capecitabine maintenance therapy improved PFS (HR:0.36, 95% CI:0.26–0.61) and reduced the risk of progression at 6 months (HR:0.78, 95% CI:0.56–1.10). The incidence of any grade ≥ 3 toxicity was higher with maintenance therapy than with observation (OR:2.02, 95% CI:1.42–2.88). No difference in terms of QoL was observed. Single-agent capecitabine as maintenance for patients with mCRC provides no OS benefit but results in statistically significant improvement in PFS with increased risk of toxicity. Hence, it may be considered particularly for patients who wish to delay the need for second-line treatment and who can tolerate it well.
{"title":"Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis","authors":"B. Ong, A. Rocimo, R. King, E. Yasay","doi":"10.1055/s-0042-1744439","DOIUrl":"https://doi.org/10.1055/s-0042-1744439","url":null,"abstract":"Many agents have been evaluated as maintenance therapy for metastatic colorectal cancer (mCRC), but there is no consensus on the optimal regimen. This study assessed the effect of single-agent capecitabine maintenance therapy on the survival outcomes of mCRC patients. A comprehensive literature search was performed according to prespecified inclusion and exclusion criteria for randomized controlled trials (RCTs) comparing capecitabine as maintenance monotherapy versus active monitoring for mCRC patients. Data on overall survival (OS), progression-free survival (PFS), time to tumor progression (TTP), adverse events, and quality of life (QoL) scores were extracted. Three RCTs with a total of 576 patients were included. Pooled analyses found neither OS benefit (HR:0.85, 95% CI:0.64–1.13) nor reduction in mortality at 24 months (RR:0.88, 95% CI:0.66–1.17) with capecitabine maintenance. Compared with active monitoring, capecitabine maintenance therapy improved PFS (HR:0.36, 95% CI:0.26–0.61) and reduced the risk of progression at 6 months (HR:0.78, 95% CI:0.56–1.10). The incidence of any grade ≥ 3 toxicity was higher with maintenance therapy than with observation (OR:2.02, 95% CI:1.42–2.88). No difference in terms of QoL was observed. Single-agent capecitabine as maintenance for patients with mCRC provides no OS benefit but results in statistically significant improvement in PFS with increased risk of toxicity. Hence, it may be considered particularly for patients who wish to delay the need for second-line treatment and who can tolerate it well.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42958843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction We retrospectively examined the changes in the management and outcomes of the cases with atypical squamous cells of undetermined significance (ASC-US) according to the Bethesda system (TBS). Materials and Methods Between May 2009 and December 2018, 432 cases with ASC-US were retrospectively examined for the implementation of high-risk human papillomavirus (hrHPV) testing and/or cervical biopsy and clinical courses. Results The hrHPV testing was performed in 277 cases (64.1%). Of these, there were 80 with positive hrHPV (28.9%). Of the 80 cases, cervical biopsy was performed in 71 (88.9%) cases based on the finding of colposcopy. Cervical intraepithelial neoplasia (CIN) was diagnosed in 55 cases (77.4%). The sensitivity, specificity, positive predictive value, and negative predictive value of CIN diagnosis by hrHPV testing in cases of ASC-US were 72.5, 95.0, 88.7, and 86.3%, respectively (p < 0.01). Conclusion The conducting of hrHPV test on women who were evaluated as ASC-US according to TBS affirmed its clinical usefulness.
{"title":"Evaluation of High-Risk Human Papillomavirus Testing in Women with Atypical Squamous Cells of Undetermined Significance to Detect Cervical Intraepithelial Neoplasia","authors":"R. Kawase, Shunji Suzuki","doi":"10.1055/s-0042-1744437","DOIUrl":"https://doi.org/10.1055/s-0042-1744437","url":null,"abstract":"\u0000 Introduction We retrospectively examined the changes in the management and outcomes of the cases with atypical squamous cells of undetermined significance (ASC-US) according to the Bethesda system (TBS).\u0000 Materials and Methods Between May 2009 and December 2018, 432 cases with ASC-US were retrospectively examined for the implementation of high-risk human papillomavirus (hrHPV) testing and/or cervical biopsy and clinical courses.\u0000 Results The hrHPV testing was performed in 277 cases (64.1%). Of these, there were 80 with positive hrHPV (28.9%). Of the 80 cases, cervical biopsy was performed in 71 (88.9%) cases based on the finding of colposcopy. Cervical intraepithelial neoplasia (CIN) was diagnosed in 55 cases (77.4%). The sensitivity, specificity, positive predictive value, and negative predictive value of CIN diagnosis by hrHPV testing in cases of ASC-US were 72.5, 95.0, 88.7, and 86.3%, respectively (p < 0.01).\u0000 Conclusion The conducting of hrHPV test on women who were evaluated as ASC-US according to TBS affirmed its clinical usefulness.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42906553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Chua, K. Yu, Patricia Andrea Chua, Raphael Joseph Chua, Robeley May Chua, Yae Na Chun, J. Mariano, G. González, T. S. Ortin, W. Bacorro
Introduction The standard treatment for locally advanced cervical cancer (LACC) is concurrent chemoradiotherapy (CRT). External beam radiotherapy (EBRT) and brachytherapy (BRT) advances in the last decade have resulted in improved local control and survival. There is a lack of data on quality of life (QoL) among survivors. Objective This systematic review aimed to synthesize published data on QoL among LACC survivors treated with CRT and determine clinical factors of QoL. Methods Systematic literature search was conducted in PubMed, EBSCO, and ScienceDirect for relevant articles published in 2010 to 2020. Eligible studies on LACC survivors aged 18 years and above, who reported QoL after CRT, were included. Screening and data extraction were done by two pairs of independent reviewers. Results Five cohort studies, three cross sectional studies, and one clinical trial were included. Reported temporal evolution of QoL varied: two studies reported improvement of overall QoL, while four reported worsening of symptoms. Gastrointestinal, genitourinary, sexual, and psychosocial domains showed significant impairment. Age, stage, and baseline distress and physical condition were clinical determinants of body image, sexual activity, menopausal symptoms, distress, and dyspnea. Peripheral neuropathy, lymphedema, and dyspnea were reported, while grade 3 to 4 gastrointestinal, genitourinary, and musculoskeletal toxicities were rare. Conclusion Use of advanced EBRT and BRT techniques is associated with improving QoL in the first 3 years from treatment completion. Gastrointestinal, genitourinary, sexual, and psychosocial functions remain impaired on the long-term. Other late toxicities worth noting include peripheral neuropathy, lower limb edema, and insufficiency fractures.
{"title":"Quality of Life among Survivors of Locally Advanced Cervical Cancer Treated with Definitive Chemoradiotherapy in a Decade of Transition","authors":"V. Chua, K. Yu, Patricia Andrea Chua, Raphael Joseph Chua, Robeley May Chua, Yae Na Chun, J. Mariano, G. González, T. S. Ortin, W. Bacorro","doi":"10.1055/s-0042-1744300","DOIUrl":"https://doi.org/10.1055/s-0042-1744300","url":null,"abstract":"\u0000 Introduction The standard treatment for locally advanced cervical cancer (LACC) is concurrent chemoradiotherapy (CRT). External beam radiotherapy (EBRT) and brachytherapy (BRT) advances in the last decade have resulted in improved local control and survival. There is a lack of data on quality of life (QoL) among survivors.\u0000 Objective This systematic review aimed to synthesize published data on QoL among LACC survivors treated with CRT and determine clinical factors of QoL.\u0000 Methods Systematic literature search was conducted in PubMed, EBSCO, and ScienceDirect for relevant articles published in 2010 to 2020. Eligible studies on LACC survivors aged 18 years and above, who reported QoL after CRT, were included. Screening and data extraction were done by two pairs of independent reviewers.\u0000 Results Five cohort studies, three cross sectional studies, and one clinical trial were included. Reported temporal evolution of QoL varied: two studies reported improvement of overall QoL, while four reported worsening of symptoms. Gastrointestinal, genitourinary, sexual, and psychosocial domains showed significant impairment. Age, stage, and baseline distress and physical condition were clinical determinants of body image, sexual activity, menopausal symptoms, distress, and dyspnea. Peripheral neuropathy, lymphedema, and dyspnea were reported, while grade 3 to 4 gastrointestinal, genitourinary, and musculoskeletal toxicities were rare.\u0000 Conclusion Use of advanced EBRT and BRT techniques is associated with improving QoL in the first 3 years from treatment completion. Gastrointestinal, genitourinary, sexual, and psychosocial functions remain impaired on the long-term. Other late toxicities worth noting include peripheral neuropathy, lower limb edema, and insufficiency fractures.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45009012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Shetty, Akash Menon, N. Sharma, Fatema Boootwala
Radical surgery is the mainstay for the treatment of recurrent ameloblastomas; however, it leads to large, complex defects. In this case report, we present an innovative technique of digitally aided resection and reconstruction. A massive histologically confirmed acanthomatous ameloblastoma of the skull-base was digitally mapped with the help of three-dimensional (3D) computed tomography and a custom resection template was fabricated. Digital resection of the skull-base tumor with intracranial extension was done virtually and the resultant defect was reconstructed to create an anatomical replica of the contralateral unaffected side. The tumor was successfully resected with adequate margins guided by the resection template to avoid injury to adjacent vital structures. Subsequent reconstruction was performed by first adapting polymethyl methacrylate bone cement into a series of custom-made 3D molds. Once set, this bone cement served as a reconstructive implant to bridge the ablative defect. The implant offered a precise fit and was secured to healthy adjacent bone using titanium microplates. We present a 6-month follow-up of the case with satisfactory aesthetic results. 3D printing technology has the potential to revolutionize the arena of craniofacial resection with excellent cosmesis and no donor site morbidity if applied appropriately as described here.
{"title":"Digital Mapping of a Massive Skull-Base Ameloblastoma with Intracranial Extension, Resection, and Reconstruction Using 3D Templates and Molds: Descriptive Case Report and Review","authors":"V. Shetty, Akash Menon, N. Sharma, Fatema Boootwala","doi":"10.1055/s-0042-1744555","DOIUrl":"https://doi.org/10.1055/s-0042-1744555","url":null,"abstract":"Radical surgery is the mainstay for the treatment of recurrent ameloblastomas; however, it leads to large, complex defects. In this case report, we present an innovative technique of digitally aided resection and reconstruction. A massive histologically confirmed acanthomatous ameloblastoma of the skull-base was digitally mapped with the help of three-dimensional (3D) computed tomography and a custom resection template was fabricated. Digital resection of the skull-base tumor with intracranial extension was done virtually and the resultant defect was reconstructed to create an anatomical replica of the contralateral unaffected side. The tumor was successfully resected with adequate margins guided by the resection template to avoid injury to adjacent vital structures. Subsequent reconstruction was performed by first adapting polymethyl methacrylate bone cement into a series of custom-made 3D molds. Once set, this bone cement served as a reconstructive implant to bridge the ablative defect. The implant offered a precise fit and was secured to healthy adjacent bone using titanium microplates. We present a 6-month follow-up of the case with satisfactory aesthetic results. 3D printing technology has the potential to revolutionize the arena of craniofacial resection with excellent cosmesis and no donor site morbidity if applied appropriately as described here.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44941749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background This review determined clinical features and treatment outcomes of retinoblastoma patients in China, which ranks second in incidence globally and is among the countries listed to produce 4,000 new cases of the estimated world's retinoblastoma cases in 2023. Methods A search was done using different databases for literatures on retinoblastoma in China published from 2010 to 2020. The articles were then reviewed for clinical features, treatment, and outcomes. Results Ten articles that included 3,702 patients involving ∼4,412 eyes seen in China from 1957 to 2019 were analyzed. Median age at consult ranged from 18 to 30 months and mean lag of consultation was 4 to 6 months. More males were affected (58%). Seventy-nine percent had unilateral disease. Retinoblastoma was assumed intraocular in 4,123(89%) eyes with ≥996(22%) belonging to group E of International Intraocular Retinoblastoma Classification/International Classification of Retinoblastoma. Extraocular extension was present in 415 (9%) eyes with 845 patients having direct extraocular extension, while 54 had distant metastasis. Enucleation was the most used treatment procedure specially in unilateral disease done in at least 2,781 (74%) eyes. Median follow-up period ranged from 14 to 47 months. Functional vision was retained in 48 (2%) eyes. Globe salvage rate for group A to D eyes ranged from 56 to 100%. Highest globe salvage rate for group D was 87% and 70% for group E. Overall survival rate was 1,655/1898 (87%), ranging from 81 to 100%. Overall mortality was 4%. Discussion Clinical profile and management options for retinoblastoma in China changed overtime improving outcomes. Globe salvage and survival rate were high for those with intraocular disease.
{"title":"Clinical Features, Treatment, and Outcomes of Retinoblastoma in China","authors":"R. J. D. Tan","doi":"10.1055/s-0042-1744449","DOIUrl":"https://doi.org/10.1055/s-0042-1744449","url":null,"abstract":"\u0000 Background This review determined clinical features and treatment outcomes of retinoblastoma patients in China, which ranks second in incidence globally and is among the countries listed to produce 4,000 new cases of the estimated world's retinoblastoma cases in 2023.\u0000 Methods A search was done using different databases for literatures on retinoblastoma in China published from 2010 to 2020. The articles were then reviewed for clinical features, treatment, and outcomes.\u0000 Results Ten articles that included 3,702 patients involving ∼4,412 eyes seen in China from 1957 to 2019 were analyzed. Median age at consult ranged from 18 to 30 months and mean lag of consultation was 4 to 6 months. More males were affected (58%). Seventy-nine percent had unilateral disease. Retinoblastoma was assumed intraocular in 4,123(89%) eyes with ≥996(22%) belonging to group E of International Intraocular Retinoblastoma Classification/International Classification of Retinoblastoma. Extraocular extension was present in 415 (9%) eyes with 845 patients having direct extraocular extension, while 54 had distant metastasis. Enucleation was the most used treatment procedure specially in unilateral disease done in at least 2,781 (74%) eyes. Median follow-up period ranged from 14 to 47 months. Functional vision was retained in 48 (2%) eyes. Globe salvage rate for group A to D eyes ranged from 56 to 100%. Highest globe salvage rate for group D was 87% and 70% for group E. Overall survival rate was 1,655/1898 (87%), ranging from 81 to 100%. Overall mortality was 4%.\u0000 Discussion Clinical profile and management options for retinoblastoma in China changed overtime improving outcomes. Globe salvage and survival rate were high for those with intraocular disease.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48423540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prasad Apsangikar, Prashant Shirsath, M. Naik, Sonya Vasudeva
Purpose The aim of this study was to compare first global biosimilar denosumab for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Methods It was a randomized, double-blind, comparative clinical study. Total of 136 patients of solid tumor were dosed (i.e., 102 subjects in study arm and 34 subjects in the reference arm) with initial double-blind period of 24 weeks (primary efficacy) followed by open-label phase till week 36. Primary endpoint was the incidence of first on-study SRE including hypercalcemia of malignancy with co-primary endpoint of median time to first on-study SRE. Secondary endpoints included mean number and time to first and subsequent on-study SREs (week 12, 24, 36), incidence/proportion of patients with first and subsequent on-study SREs (week 24, 36), change from baseline in nuclear bone scan, quality of life assessment, pharmacokinetics, pharmacodynamic, and safety. Results In biosimilar study arm, 06 (5.83%) patients suffered SRE from baseline to week 24 compared with 02 (5.71%) patients in reference arm with one (0.97%) patient showing pathological fracture in study arm and one (2.86%) patient having spinal cord compression in reference arm. There was no statistically significant difference in median time to first SRE, mean number of SRE/patient in both arms and improvement in bone repair on nuclear scan at 12, 24 and 36 weeks. Though the study arm showed better health-related quality of life (HRQoL), mean change in HRQoL was statistically not different in both the arms. Pharmacodynamics, serum bone-specific alkaline phosphatase, pharmacokinetic and safety evaluation did not show any statistical difference between arms. Conclusion There was no clinically meaningful difference in the biosimilar denosumab and reference product after detailed efficacy and safety evaluation.
{"title":"Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology","authors":"Prasad Apsangikar, Prashant Shirsath, M. Naik, Sonya Vasudeva","doi":"10.1055/s-0042-1744505","DOIUrl":"https://doi.org/10.1055/s-0042-1744505","url":null,"abstract":"\u0000 Purpose The aim of this study was to compare first global biosimilar denosumab for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.\u0000 Methods It was a randomized, double-blind, comparative clinical study. Total of 136 patients of solid tumor were dosed (i.e., 102 subjects in study arm and 34 subjects in the reference arm) with initial double-blind period of 24 weeks (primary efficacy) followed by open-label phase till week 36. Primary endpoint was the incidence of first on-study SRE including hypercalcemia of malignancy with co-primary endpoint of median time to first on-study SRE. Secondary endpoints included mean number and time to first and subsequent on-study SREs (week 12, 24, 36), incidence/proportion of patients with first and subsequent on-study SREs (week 24, 36), change from baseline in nuclear bone scan, quality of life assessment, pharmacokinetics, pharmacodynamic, and safety.\u0000 Results In biosimilar study arm, 06 (5.83%) patients suffered SRE from baseline to week 24 compared with 02 (5.71%) patients in reference arm with one (0.97%) patient showing pathological fracture in study arm and one (2.86%) patient having spinal cord compression in reference arm. There was no statistically significant difference in median time to first SRE, mean number of SRE/patient in both arms and improvement in bone repair on nuclear scan at 12, 24 and 36 weeks. Though the study arm showed better health-related quality of life (HRQoL), mean change in HRQoL was statistically not different in both the arms. Pharmacodynamics, serum bone-specific alkaline phosphatase, pharmacokinetic and safety evaluation did not show any statistical difference between arms.\u0000 Conclusion There was no clinically meaningful difference in the biosimilar denosumab and reference product after detailed efficacy and safety evaluation.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45812247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：